PS
AUTL

Principal Securities’s Autolus Therapeutics AUTL Stock Holding History

Principal Securities’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37
Closed -$60 – 1510
2025
Q3 		$60 Hold
37
– – ﹤0.01% 3714
2025
Q2 		$84 Buy
+37
New +$61 ﹤0.01% 3650

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Principal Securities's AUTL Position: Q4 2025 in Review

Principal Securities sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 37 shares — an estimated $60 sold.

Principal Securities first reported a position in AUTL in Q2 2025 and held it in 2 quarters. The position peaked at $84 in Q2 2025. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Principal Securities reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 37 Autolus Therapeutics shares in Q4 2025, an estimated $60.
  • Principal Securities first reported a position in Autolus Therapeutics in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Autolus Therapeutics position peaked at $84 in Q2 2025.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.